A venture company created by researchers at Keio University has announced that it has performed surgery to process heart muscle cells made from iPS cells into spherical shapes and transplant them to patients with severe heart disease.
We are aiming for national approval because it was conducted as a clinical trial.
This was announced at a press conference between a medical venture company launched by Professor Keiichi Fukuda of Keio University School of Medicine and a doctor at Tokyo Women's Medical University Hospital who performed the surgery.
This company is developing a new treatment method that creates heart muscle cells and cardiomyocytes from iPS cells, processes them into spheres, and transplants them into the hearts of patients with severe heart failure by injection.
According to the announcement, the first patient's surgery was performed at Tokyo Women's Medical University Hospital in December last year as a clinical trial to obtain national approval.
The patient is a man in his 60s who has suffered a myocardial infarction and is in a state of severe heart failure. It means that it was injected and transplanted in 15 places.
According to Professor Fukuda, the transplantation can be expected to restore heart function, and so far there have been no problems with the patient's condition, and the safety and efficacy will be confirmed over the next six months to a year.
Professor Fukuda said, ``I have thought that it is more important than ever to reflect research in clinical practice.It is a very big step.